Group 1 - The core viewpoint of the article highlights Modern Dental's financial performance for the year ending December 31, 2024, with a revenue of HKD 3.364 billion, a year-on-year increase of 6.05%, and a net profit attributable to shareholders of HKD 408 million, reflecting a growth of 0.97% [1] - The company plans to enhance its product offerings and market coverage through the acquisition of Thailand's largest dental laboratory, Hexa Ceram Company Limited, expected to be completed in January 2025 [1] - Modern Dental is actively involved in the integration of the dental prosthetics industry, with full operations at its factories in Vietnam and Dongguan, aiming to capitalize on global digitalization trends [1] Group 2 - The ongoing global digitalization trend is driving the integration of the dental prosthetics industry, allowing the company to increase its market share and improve customer and patient experiences, setting it apart from competitors [1] - The company's sales growth indicates robust operational and financial performance across its markets, demonstrating its ability to deliver strong financial results amid a stable operating environment characterized by increasing order volumes and competitive positioning [1] - The company possesses significant advantages in the current uncertain macroeconomic environment, with onshore production capabilities in the U.S. and production facilities in Southeast Asia, which help mitigate tariff-related risks while seizing opportunities [2]

（於開曼群島註冊成立的有限公司） （股份代號：3600） 張惠彬博士，太平紳士 （主席） 陳裕光博士 邱家寶醫生 自二零二五年四月一日起，現代牙科集團有限公司董事會（「董事會」）成員載列如下。 執行董事 陳奕朗醫生 （主席及行政總裁） 陳奕茹女士 （市場推廣總監） 陳冠斌先生 陳志遠先生 非執行董事 陳冠峰先生 獨立非執行董事 張惠彬博士，太平紳士 陳裕光博士 張偉民博士 邱家寶醫生 董事會已設立三個委員會。該等委員會之組成及各董事會成員所擔任之職位載列如下： 審核委員會 董事名單與其角色和職能 提名委員會 陳裕光博士 （主席） 張惠彬博士，太平紳士 張偉民博士 陳奕朗醫生 薪酬委員會 張偉民博士 （主席） 張惠彬博士，太平紳士 邱家寶醫生 陳奕茹女士 香港，2025年3月27日 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：3600） 董事調任 現代牙科集團有限公司（「本公司」及其附屬公司「本集團」）董事（「董事」）會（「董事 會」）宣佈，目前擔任本公司執行董事的陳冠峰先生（「陳冠峰先生」）將轉為擔任非 執行董事的職務，自2025年4月1日起生效，為新一代領導層鋪路。陳冠峰先生在 本集團內的角色將轉型為導師及顧問，為董事會提供客觀意見及協助制定策略及政 策。 本公司謹此對陳冠峰先生於任職執行董事期間對本公司所作出之寶貴貢獻致以衷心 謝意。 陳冠峰先生，70歲，為本公司若干附屬公司的董事及監事。彼主要負責本集團的整 體策略規劃及管理。 – 1 – 於2015年8月10日，陳冠峰先生及陳冠斌先生簽署確認函，確認彼等的一致行動安 排，據此彼等透過討論共同營運本集團，並於為本集團作出任何商業決定前達成一 致共識。 陳冠峰先生為本公司主要股東（定義見證券及期貨條例第XV部）Triera ...

EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 現代牙科集團有限公司 (於開曼群島註冊成立的有限公司) | | 股份代號 | 03600 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度之末期股息 | | 公告日期 | 2025年3月27日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 股 0.092 HKD | | 股東批准日期 | 2025年5月29日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.092 HKD | ...

Financial Performance - For the fiscal year ending December 31, 2024, the company's revenue was approximately HKD 3,364,018,000, representing an increase of about 6.1% compared to HKD 3,172,048,000 in 2023[5] - The gross profit for the same period was approximately HKD 1,798,871,000, reflecting a growth of about 5.8% from HKD 1,700,693,000 in 2023, with a gross margin of approximately 53.5%[5] - The company's EBITDA for the fiscal year was approximately HKD 708,796,000, an increase of about 2.1% from HKD 694,471,000 in 2023[5] - Adjusted EBITDA for the fiscal year was approximately HKD 741,481,000, which is an increase of about 6.9% compared to HKD 693,899,000 in 2023[6] - The net profit for the fiscal year was approximately HKD 406,943,000, showing a growth of about 1.2% from HKD 402,177,000 in 2023[5] - The total revenue for the year ended December 31, 2024, was HKD 3,364,018,000, representing a 6.05% increase from HKD 3,172,048,000 in 2023[14] - Gross profit for the same period was HKD 1,798,871,000, up from HKD 1,700,693,000, indicating a growth of 5.78%[14] - The net profit for the year was HKD 406,943,000, slightly increasing from HKD 402,177,000, which is a 1.91% rise[14] - Basic and diluted earnings per share for the company were both HKD 0.432, compared to HKD 0.424 in the previous year, reflecting a 1.89% increase[14] Market Performance - Revenue from the European market increased by 16.1%, while the North American market (excluding MicroDental) saw an increase of approximately 8.7%[12] - Revenue from the European market for the year ended December 31, 2024, was approximately HKD 1,618,436,000, an increase of about HKD 219,065,000 from the previous year, representing 48.1% of total revenue[72] - North American market revenue for the year ended December 31, 2024, was approximately HKD 752,083,000, a decrease of about HKD 1,532,000 from the previous year, accounting for 22.3% of total revenue[73] - Revenue from the Greater China market for the year ended December 31, 2024, was approximately HKD 662,210,000, a decrease of about HKD 51,382,000 from the previous year, representing 19.7% of total revenue[76] - The Australian market recorded revenue of approximately HKD 264,752,000 for the year ended December 31, 2024, an increase of about HKD 10,411,000 from the previous year, accounting for 7.9% of total revenue[77] Acquisitions and Investments - The company acquired Thailand's largest dental laboratory, Hexa Ceram Company Limited, in January 2025, which is expected to enhance its product offerings and market coverage[3] - The company plans to acquire 74% equity in Hexa Ceram Company Limited for a cash consideration of approximately THB 938,959,000 (about HKD 214,102,000), expected to complete in January 2025[55] - The company plans to acquire 25% of Hexa Ceram Company Limited for a total consideration of THB 326,216,000 (approximately HKD 74,384,000)[108] - The company also intends to purchase 49% of Hexa Ceram Company Limited for THB 612,743,000 (approximately HKD 139,718,000)[109] Production and Operations - The company produced approximately 769,564 digital solutions cases in mainland China and Vietnam, a significant increase of 36.0% from approximately 565,891 cases in 2023, driven by greater adoption of intraoral scanners[7] - The company maintained onshore production capabilities in the U.S. and production facilities in Southeast Asia, which mitigated tariff-related risks and leveraged opportunities[4] - The company has established a new production facility in Vietnam to mitigate risks associated with its existing production bases in Shenzhen and Dongguan[118] Financial Position - Non-current assets totaled HKD 2,326,274,000, a decrease from HKD 2,381,523,000 in 2023, representing a decline of 2.32%[16] - Current assets increased to HKD 1,748,581,000 from HKD 1,571,324,000, marking an increase of 11.27%[16] - The company's total liabilities were HKD 1,349,281,000, compared to HKD 1,309,746,000 in 2023, indicating a rise of 2.99%[17] - The net asset value increased to HKD 2,725,574,000 from HKD 2,643,101,000, reflecting a growth of 3.11%[17] - The debt ratio improved to approximately 14% in 2024 from 16% in 2023, indicating a stable financial position[103] Dividends - The board proposed a final dividend of HKD 0.092 per share for the fiscal year, up from HKD 0.090 per share in 2023, pending shareholder approval[6] - The interim dividend for 2024 is proposed at HKD 0.08 per share, up from HKD 0.06 per share in 2023, totaling HKD 75,752,000[41] - The proposed final dividend for 2024 is HKD 0.092 per share, compared to HKD 0.09 per share in 2023, amounting to HKD 86,855,000[42] Employee and Operational Costs - The total employee cost for the fiscal year ending December 31, 2024, was approximately HKD 1,532,248,000, an increase from HKD 1,439,045,000 in 2023[123] - The company employed a total of 7,106 full-time employees as of December 31, 2024, compared to 7,035 in 2023[123] Risks and Challenges - The company faces various business risks, including global economic fluctuations and geopolitical risks, which may significantly impact its financial condition and operating performance[115] - The company has not established any interest rate agreements or derivative transactions to hedge against interest rate fluctuations[119] Corporate Governance - The company has complied with the corporate governance code as per the listing rules for the year ending December 31, 2024[133] - The audit committee reviewed the group's financial performance and accounting principles for the year ending December 31, 2024[135] - The annual results announcement will be published on the Hong Kong Stock Exchange and the company's website[137]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 承董事會命 （於開曼群島註冊成立的有限公司） （股份代號：3600） 董事會召開日期 現代牙科集團有限公司（「本公司」及其附屬公司「本集團」）董事會（「董事會」）茲通告 謹定於2025年3月27日（星期四）舉行董事會會議，以（當中包括）考慮及通過本集團 截至2024年12月31日止年度末期業績及其刊發，及考慮股息的宣派、建議或派發 （如有）。 陳奕朗 香港，2025年3月13日 於本公告日期，本公司董事會包括執行董事陳奕朗、陳奕茹、陳冠峰、陳冠斌、陳志遠， 以及獨立非執行董事張惠彬太平紳士、陳裕光、張偉民及邱家寶。 現代牙科集團有限公司 主席兼行政總裁 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 03600 | 說明 | 股份回購 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年1月23日 | | 944,077,000 | | 0 | | 944,077,000 | | 1). 其他 (請註明) | | | | % ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 現代牙科集團有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年1月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 | 1). | 購回股份擬註銷但尚未註銷 | | 100,000 | % | HKD | 3.9922 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2024年12月3日 | | | | | | 2). | 購回股份擬註銷但尚未註銷 | | 100,000 | % | HKD | 4.0025 | | | 變動日期 | 2024年12月4日 | | | | | | 3). | 購回股份擬註銷但尚未註銷 | | 100,000 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 現代牙科集團有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2025年1月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 03600 | 說明 | 股份回購 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行 ...

公司名稱： 現代牙科集團有限公司 (於開曼群島註冊成立的有限公司) FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2025年1月21日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 03600 | 說明 | 股份回購 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行 ...